Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study

Rhea-AI Summary

Propanc Biopharma (Nasdaq: PPCB) executed a service agreement with FyoniBio to develop and validate an LC-MS pharmacokinetics (PK) assay for its lead asset PRP (trypsinogen and chymotrypsinogen plus activated enzymes) to support a Phase 1b First‑In‑Human study in advanced solid tumor patients. The assay aims for ≤0.1µg/mL sensitivity to quantify four serum analytes. Propanc cites assay validation, GMP manufacture of PRP, and a clinical trial application as three key preparatory activities, and plans to commence the FIH study in the fourth calendar quarter of 2026.

Positive

• Contracted FyoniBio to establish validated LC‑MS PK assay
• Target assay sensitivity of 0.1µg/mL for four analytes
• Phase 1b First‑In‑Human study planned for Q4 2026

Negative

• PK assay not yet validated, posing potential trial start delays
• FIH study dependent on GMP manufacture and clinical trial application

Market Reaction – PPCB

-11.22% $0.15 2.1x vol

15m delay 9 alerts

-11.22% Since News

$0.15 Last Price

$0.15 $0.16 Day Range

-$306K Valuation Impact

$2M Market Cap

2.1x Rel. Volume

Following this news, PPCB has declined 11.22%, reflecting a significant negative market reaction. Our momentum scanner has triggered 9 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $0.15. This price movement has removed approximately $306K from the company's valuation. Trading volume is elevated at 2.1x the average, suggesting increased selling activity.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.

Key Figures

Assay sensitivity: 0.1µg/mL

1 metrics

Assay sensitivity 0.1µg/mL Maximum sensitivity target for LC‑MS PK assay in Phase 1b FIH study

Market Reality Check

Price: $0.1720 Vol: Volume 717,129 is about 0...

low vol

$0.1720 Last Close

Volume Volume 717,129 is about 0.5x the 20-day average of 1,440,760, suggesting muted trading interest before this update. low

Technical Shares at $0.172 are trading well below the 200-day MA of $2.29 and 99.28% under the 52-week high, despite sitting 10.61% above the 52-week low.

Peers on Argus

PPCB gained 1.78% while closely ranked peers showed mixed moves: LIXT up 5.02%, ...

2 Up

PPCB gained 1.78% while closely ranked peers showed mixed moves: LIXT up 5.02%, ALLR up 2.89%, AKTX, BOLD and RNTX modestly down. Momentum scans flagged ALLR and RLYB with gains of 6.45% and 3.48%, but PPCB’s move appears stock-specific rather than a broad biotech rotation.

Historical Context

5 past events · Latest: Mar 03 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 03	Preclinical efficacy update	Positive	-5.2%	Highlighted >85% tumor growth inhibition and Phase 1b plans for PRP.
Feb 18	Corporate update, results	Positive	-4.5%	Reported IP expansion, peer‑reviewed PRP data, and private placement facility.
Feb 05	PRP positioning news	Positive	+5.7%	Detailed PRP’s mechanism, orphan status, and 2026 Phase 1b trial plan.
Jan 27	Patent portfolio update	Positive	+6.5%	Filed fourth provisional patent to bolster PRP formulations and global IP.
Jan 20	New patent filing	Positive	-4.7%	Filed provisional patent for synthetic Rec‑PRP manufacturing methods.

Pattern Detected

Recent news has been largely positive on PRP and IP, yet price reactions were mixed, with more negative than positive moves, indicating frequent sell-the-news or liquidity-driven responses.

Recent Company History

Over the last few months, Propanc Biopharma has focused on advancing its lead asset PRP and expanding intellectual property. Releases on Jan 20 and Jan 27 highlighted new provisional patents and formulation improvements. Early February and early March news emphasized PRP’s >85% tumor growth inhibition, orphan drug status, and plans for a Phase 1b first-in-human trial. Despite these milestones, several updates saw negative price reactions. Today’s PK assay agreement fits this pattern of incremental de‑risking steps toward the planned clinical study.

Market Pulse Summary

The stock is dropping -11.2% following this news. A negative reaction despite operational progress w...

Analysis

The stock is dropping -11.2% following this news. A negative reaction despite operational progress would fit a pattern where positive PRP and IP news sometimes preceded declines, as seen after several early‑2026 releases. The assay agreement advances readiness for the planned Phase 1b first‑in‑human trial but arrives against a backdrop of substantial losses, recent resale registrations, and a share price sitting 99.28% below its 52‑week high. In such conditions, liquidity, dilution concerns, or profit‑taking have previously outweighed fundamental milestones in the short term.

Key Terms

liquid chromatography-mass spectrometry (LC-MS), pharmacokinetics (PK), first-in-human (FIH), serum, +2 more

6 terms

liquid chromatography-mass spectrometry (LC-MS) technical

"for establishing and validating a liquid chromatography-mass spectrometry (LC-MS) based"

An analytical lab technique that first separates a mixture into its components (like passing a soup through finer and finer sieves) and then measures each component’s unique mass signature (like taking a molecular fingerprint). Investors care because LC-MS is a primary tool for verifying drug purity, detecting trace contaminants, measuring biomarker levels in trials, and supporting regulatory filings—results that affect a product’s safety, approval prospects, and commercial value.

pharmacokinetics (PK) medical

"based pharmacokinetics (PK) assay. The objective is to quantify the Company’s"

Pharmacokinetics (PK) is the study of how a drug moves through and is processed by the body over time. It tracks how quickly a drug is absorbed, how it spreads, how it is broken down, and how it exits the body—similar to following a recipe’s ingredients from start to finish. For investors, understanding pharmacokinetics helps assess a drug’s effectiveness and safety, which can influence its market potential and valuation.

first-in-human (FIH) medical

"during the Phase 1b, First-In-Human (FIH) study in advanced cancer patients"

The first-in-human (FIH) designation marks the first time a new drug, vaccine, medical device, or treatment is given to people rather than tested only in labs or animals. For investors, FIH is a major milestone because it moves a candidate from preclinical testing into human safety and early effectiveness evaluation—think of it as the prototype being driven on public roads, where results strongly influence future development costs, timelines, and commercial potential.

serum medical

"trypsin and chymotrypsin from human serum during the Phase 1b, First-In-Human"

The clear, yellowish fluid obtained from blood after clotting has been removed; it contains proteins, antibodies and other molecules used to measure health markers. Investors pay attention because serum is the sample used in many medical tests, drug development studies and regulatory safety checks—results from those tests can change a therapy’s market prospects much like a quality report can sway a product’s sales outlook.

gmp manufacture technical

"The other two are the GMP manufacture of PRP and clinical trial"

GMP manufacture means producing medicines, medical devices or related products under a set of widely accepted quality rules called Good Manufacturing Practice (GMP). Think of it as following a detailed recipe and strict kitchen hygiene so every batch is safe, consistent and traceable; for investors, GMP compliance reduces the risk of regulatory shutdowns, product recalls, legal penalties and lost revenue, and it often determines whether a product can be sold or trusted in major markets.

clinical trial application regulatory

"are the GMP manufacture of PRP and clinical trial application for the study"

An application submitted to a regulatory authority requesting formal permission to begin testing a new drug, medical device, or treatment in humans. Like asking for a building permit before construction, it summarizes safety data, plans for how the study will be run, and monitoring procedures; investors watch these filings closely because approval lets a program move from lab research to clinical testing, reducing uncertainty and creating value-driving milestones.

AI-generated analysis. Not financial advice.

A German CDO Supporting Biotech Companies Bringing Biologics from Early Development to Clinic

MELBOURNE, Australia, March 10, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced that management has executed a service agreement with FyoniBio GmbH (formerly Glycotope, est. 2010), a German Contract Development Organization (CDO) based in Berlin for establishing and validating a liquid chromatography-mass spectrometry (LC-MS) based pharmacokinetics (PK) assay. The objective is to quantify the Company’s lead asset, PRP, consisting of two proenzymes trypsinogen and chymotrypsinogen, as well as their activated enzyme forms trypsin and chymotrypsin from human serum during the Phase 1b, First-In-Human (FIH) study in advanced cancer patients suffering from solid tumors.

The purpose and design of the study will be used as an important tool to measure the concentration of PRP and its analytes over time upon administration to advanced cancer patients suffering from solid tumors. Results from the PK assay will evaluate the systemic concentration of PRP sufficient to expect anti-tumor activity in patients whilst carefully evaluating their response according to safety and tolerability parameters. Secondary efficacy endpoints will also be observed to support duration of treatment for responders. The LC-MS PK assay should offer a robust method to quantify all four analytes in patients’ serum with a maximum sensitivity of at least 0.1µg/mL, sufficient to monitor the concentration of PRP in patients during the FIH study.

“Establishing and validating our PK method for the First-In-Human study is one of three key activities in preparation for this pivotal milestone. The other two are the GMP manufacture of PRP and clinical trial application for the study which we are actively undertaking,” said Dr Ralf Brandt, Propanc’s Research and Development Director. “FyoniBio provides expertise in assisting biotech companies bringing biologics from early development to the clinic. My clinical research team and I are confident that the method development work initiated will successfully translate into a fully validated method that will support our team’s decision-making processes for the upcoming study which we plan to commence in the fourth calendar quarter of this year.”

About Propanc Biopharma, Inc.

Propanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells through proenzyme activation. The Company’s lead product candidate, PRP, is designed to address the underlying drivers of cancer proliferation and spread.

More information: www.propanc.com

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements because of several factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under “Risk Factors” in the prospectus related to the proposed offering and those described in the Company’s filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

Company:
Propanc Biopharma, Inc.
James Nathanielsz

+61-3-9882-0780
info@propanc.com

Investor Contact:
irteam@propanc.com

FAQ

What did Propanc (PPCB) announce about the PK assay for PRP on March 10, 2026?

They signed a service agreement with FyoniBio to develop and validate an LC‑MS PK assay for PRP. According to the company, the assay will quantify four analytes in serum with a target sensitivity of 0.1µg/mL to support the Phase 1b study.

How will the validated PK assay affect Propanc (PPCB) Phase 1b study timelines?

A validated assay is required before dosing in the FIH study and could affect start timing. According to the company, assay validation, GMP manufacture, and the clinical trial application are three preparatory activities targeting a Q4 2026 study start.

What analytes will the Propanc (PPCB) LC‑MS PK assay measure during the FIH study?

The assay will quantify PRP components: two proenzymes and two activated enzymes. According to the company, it will measure trypsinogen, chymotrypsinogen, trypsin, and chymotrypsin concentrations in human serum over time.

What sensitivity does Propanc (PPCB) expect from the LC‑MS PK assay developed by FyoniBio?

Propanc targets a maximum sensitivity of at least 0.1µg/mL for the PK assay. According to the company, this sensitivity should be sufficient to monitor PRP systemic concentrations during the Phase 1b FIH study.

What are the remaining preclinical and regulatory steps for Propanc (PPCB) before starting the FIH study?

Key remaining steps are assay validation, GMP manufacture of PRP, and filing the clinical trial application. According to the company, those three activities are being actively undertaken ahead of a planned Q4 2026 commencement.